A carregar...
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations. Here, dasatinib efficacy was analyzed in patients recruited to phase 2/3 trials with chronic-phase chronic myeloid leukemia with o...
Na minha lista:
Publicado no: | Blood |
---|---|
Main Authors: | , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
American Society of Hematology
2009
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4916940/ https://ncbi.nlm.nih.gov/pubmed/19779040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-04-214221 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|